Faced with a dire shortage of medicines, supplies and medical personnel despite the authorities’ claims about the quality of ...

More adverse events were reported in patients on the ATEV treatment arm than those on the AV fistula treatment arm. The company later detailed safety data. Treatment-Emergent Adverse Events (TEAEs ...

Many patients undergoing dialysis rely on a vascular access site created in the arm called an arteriovenous (AV) fistula (surgically joining an artery and vein) or an AV graft (a soft tube placed ...

Many patients undergoing dialysis rely on a vascular access site created in the arm called an arteriovenous (AV) fistula (surgically joining an artery and vein) or an AV graft (a soft tube placed in ...

The device is designed to extend long-term vessel patency in dialysis patients, who rely on a vascular access site created in the arm called an arteriovenous or AV fistula or an AV graft.

Blood was everywhere. On the floor. In the chair. On the shelves and on the medical device that you can’t help but spot when you walk through the front door. It was a horrific scene, no doubt. However ...

fistulas or grafts in the arm. These sites are critical for maintaining blood flow and patient survival but are prone to complications like narrowing (stenosis) and blood clot formation ...

There is currently no cure for FSGS, which is the leading cause of kidney failure in children, and 5,400 patients are diagnosed with it every year. While 1,000 patients receive kidney transplants ...

Harsoria said it will use the funding to expand its manufacturing capabilities, improve research and development (R&D) ...

Adequate vascular access is essential for patients undergoing hemodialysis. When possible, the creation of an arteriovenous fistula using native veins will provide the highest long-term patency and ...

Autologous arteriovenous access is the key to long-term success with hemodialysis and is strongly supported by the National Kidney Foundation's Dialysis Outcomes Quality Initiative guidelines.

On September 16, 2024, the company announced that the 6-month findings from AV fistula arm of WAVE were presented at CIRSE 2024, the Cardiovascular and Interventional Radiological Society of Europe ...